Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study

Manesis, Emanuel K.; Vourli, Georgia; Dalekos, George Ν.; Vasiliadis, Themistoklis; Manolaki, Nina; Hounta, Athina; Koutsounas, S.; Vafiadis, Irini; Nikolopoulou, Georgia; Giannoulis, Gregory; Germanidis, G.; Papatheodoridis, George V.; Touloumi, Giota

doi:10.1016/j.jhep.2013.07.005

Cited by 109 publications

(127 citation statements)

References 21 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, long-term follow-up studies suggest that an IFNa based therapy per se can be taken as an independent factor associated with a lower likelihood of disease progression, and to develop clinical endpoints. 162,170 Neither NAs nor ribavirin showed significant effects on HDV RNA levels in patients with HDV infection. 1 Although HDV is often the predominant virus in this co-infection, considerable fluctuating activity of HDV and HBV or both viruses, including alternating predominance can be seen during the natural history of this chronic co-infection.…”

Section: Hdv Co-infected Patients Recommendationsmentioning

confidence: 99%

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Lampertico¹,

Agarwal²,

Berg³

et al. 2017

Journal of Hepatology

Self Cite

4,032

3,081

View full text Add to dashboard Cite

Section: Hdv Co-infected Patients Recommendationsmentioning

confidence: 99%

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Lampertico¹,

Agarwal²,

Berg³

et al. 2017

Journal of Hepatology

Self Cite

4,032

3,081

View full text Add to dashboard Cite

“…HDV is responsible for much more severe liver disease, with more frequent occurrence of fulminant hepatitis and more rapid evolution to cirrhosis and hepatocellular carcinoma (HCC) in HBV/HDV-infected patients (1)(2)(3)(4)(5). The diagnosis of HDV infection relies upon the detection of total anti-HDV antibodies.…”

mentioning

confidence: 99%

Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification

et al. 2017

View full text Add to dashboard Cite

Hepatitis D virus (HDV) is responsible for fulminant hepatitis and liver failure and accelerates evolution toward cirrhosis and hepatocellular carcinoma in hepatitis B virus (HBV)-infected patients. To date, treatment relies upon long-term administration of pegylated alpha-interferon with a sustained virological response in 30% of the patients. Very recently, new, promising anti-HDV therapies have been developed and are already being used in clinical trials. HDV RNA viral load (HDVL) monitoring must be an integral part of the management of the infected patients. However, HDV genus is characterized by a high genetic variability into eight genotypes (HDV-1 to -8), and most available in-house or commercial assays are useful for only a limited subset of genotypes. Results of a comparison of the performance of a new kit for HDVL quantification with the consensus in-house assay of the French National Reference Laboratory for HDV developed in 2005 are reported here. A total of 611 clinical samples of all HDV genotypes with various HDVL values, including several consecutive samples over several years from 36 patients, were studied. A specificity, sensitivity, and reproducibility evaluation was conducted using HDV-positive clinical samples, hepatitis A, B, C and E (HAV, HBV, HCV, and HEV, respectively) and HIV mono-infected samples, and the WHO HDV RNA international standard. Overall results were strictly comparable between the two assays (median difference, 0.07 log IU/ml), with high diagnosis precision and capacity. In summary, this new kit showed high performance in detection/quantification of HDVL, regardless of the genotype of the infecting strain used, and seems to be a suitable tool for patient management.

show abstract

“…In a study reported from Greece, Manesis et al (23) reported that anti-HDV was examined in one third of patients with positive HBsAg and it was reported that 4.7% of them were positive. Since HDV infection is a rapidly progressing disease, interferonbased treatments may change its progression.…”

Section: Discussionmentioning

confidence: 99%

The Distribution Clinical and Demographic Features of HBsAg Positive Patients in Şanlıurfa Region

Uyanıkoğlu¹,

Sert²,

Çetin³

et al. 2015

vhd

View full text Add to dashboard Cite

ÖZObjective: The objective of this study was to investigate the distribution of the clinic and demographic characteristics of hepatitis b surface antigen (HBsAg) positive patients in Şanlıurfa region. 49±15 years, range: 20-73) and 24 (83%) were male. Seventeen patients (5%) (mean age: 37.8±12.8 years, range: 16-60) were antihepatitis D virus (anti-HDV) positive, 11 (65%) were male, 5 of them were in the cirrhotic stage. Two patients (0.6%) had HBV/HCV coinfection, two patients (0.6%) had hepatocellular carcinoma (HCC). Seven patients were pregnant, three patients were given tenofovir in the 3 rd trimester, due to high viral load. Seventy one of 73 (26%) patients who were identified to have cirrhosis or chronic hepatitis due to HBV or HDV, 71 of (those who received or completed interferon treatment) received antiviral therapy, most commonly tenofovir. Liver transplantation was performed in two patients (0.6%) due to HBV related liver cirrhosis. Conclusion: Three-quarters HBsAg seropositive patients in Şanlıurfa region were inactive HBV carriers and one quarter were at the stage of chronic hepatitis or cirrhosis. Inactive carriers and chronic hepatitis patients are often in the 3 rd decade and cirrhotic patients were in the 4 th decade of life. Chronic HDV was observed in 5% of patients, HBV related HCC 0.6%, HBV/HCV co-infection was found in 0.6% of patients. Almost all patients with chronic hepatitis or cirrhosis were found to be received or/receiving antiviral treatment and the most commonly used medication was tenofovir.

show abstract

Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study

Cited by 109 publications

References 21 publications

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification

The Distribution Clinical and Demographic Features of HBsAg Positive Patients in Şanlıurfa Region

Contact Info

Product

Resources

About